Moderna (MRNA) PT Lowered to $130 at BofA Securities
Tweet
Share
E-mailGet Alerts MRNA Hot Sheet
Price: $64.97 +2.61%
Rating Summary:
5 Buy, 21 Hold, 4 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 20
Rating Summary:
5 Buy, 21 Hold, 4 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 20
Join SI Premium – FREE
BofA Securities analyst Geoff Meacham lowered the price target on Moderna (NASDAQ: MRNA) to $130.00 (from $150.00) while maintaining a Neutral rating.
You May Also Be Interested In
- Nomura/Instinet Downgrades Brother Industries Ltd (6448:JP) to Neutral
- RCM Technologies (RCMT) PT Raised to $45 at Benchmark on Q2 Beat
- Broadridge Financial (BR) PT Raised to $180 at UBS, Neutral Rating Maintained
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
